CD20 negative

P1/2, N=11, Completed, Mayo Clinic | Active, not recruiting --> Completed

Together these findings are consistent with a diagnosis of naturally occurring NK-cell lymphoproliferative disorder. NK-cell lymphoproliferative disorder has not been reported previously in rhesus macaques, to our knowledge.

We evaluated IPH6501, a clinical-stage, tetraspecific NK cell engager (NKCE) armed with a non-alpha IL-2 variant (IL-2v), which targets CD20 and was developed for treating B cell non-Hodgkin lymphoma (B-NHL)...In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that CD20-NKCE-IL2v induces peripheral NK cell homing at the tumor site. CD20-NKCE-IL2v emerges as a potential alternative in the treatment landscape of B-NHL.

Median prior lines of therapy was 3 (range 2–12), 18 (38%) pts received prior lenalidomide–based therapy, 7 (15%) pts received prior chimeric antigen receptor T-cell therapy (CAR-T), and 4 (9%) received prior CD20 TCE therapy. The exposure-response analysis supports the target dose of 7.2 mg. Further studies of AZD0486 are planned as monotherapy and in combination regimens.

P1/2, N=95, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Mar 2026 --> Sep 2024

No abstract available

P2, N=60, Recruiting, Juventas Cell Therapy Ltd. | Trial primary completion date: Jun 2024 --> Dec 2024

P1/2, N=11, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025

The addition of bortezomib, lenalidomide, or daratumumab might improve outcomes. Including PBL patients and their participation in prospective clinical trials is warranted.

P1, N=55, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Terminated due to slow enrollment and end of funding

P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=359, Active, not recruiting, Kite, A Gilead Company | Trial completion date: Jan 2035 --> Oct 2024

P1, N=52, Active, not recruiting, Stanford University | Trial completion date: Dec 2024 --> Dec 2037

P2, N=60, Recruiting, Juventas Cell Therapy Ltd. | Trial primary completion date: Dec 2023 --> Jun 2024

P1, N=6, Terminated, Kite, A Gilead Company | Phase classification: P1/2 --> P1

P1/2, N=33, Recruiting, Han weidong | Trial primary completion date: Dec 2023 --> Dec 2024

Biopsy-proven target-negative tumours showed irreversible uptake of 89Zr-mAbs measured in vivo using 89Zr-immuno-PET data, which suggests the presence of non-specific irreversible uptake in tumours. Consequently, for 89Zr-immuno-PET, even if the target is absent, a tumour-to-plasma ratio always increases over time.

This condition is frequently associated with infections caused by the Epstein-Barr virus and genetic alterations involving the MYC gene. Despite advances in our comprehension of this disease, the prognosis remains dismal, resulting in a low overall survival rate, although recent reports suggest an apparent tendency towards substantial improvement.

P1, N=52, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=92 --> 52 | Trial completion date: Sep 2034 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024

P1/2, N=73, Completed, Autolus Limited | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023

P1/2, N=116, Recruiting, Kite, A Gilead Company

P1, N=29, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University | Not yet recruiting --> Recruiting

We found that higher infused numbers of CD8 + CAR T cells with T N or T CM phenotypes, or low expression of certain exhaustion phenotype marker combinations, were associated with improved CAR-T expansion. We did not find any notable phenotypic signatures at baseline or in the IP that were predictive of prolonged CR, PFS, or toxicity, though the analysis was limited by a relatively small sample size. In FL, where a response to CAR-T therapy is almost universal, pre-manufacture and IP T cell phenotypes appear to have a lower importance for achieving an initial response than what has been reported in other settings with lower response rates (chronic lymphocytic leukemia, large B cell lymphoma).

We find that CD20 expression before treatment is an important prognostic factor, as patients with lymphomas with weak CD20 expression yield significantly poorer responses and decreased overall survival. Additionally, we find that BCL6 rearrangement is associated with superior overall survival in patients treated with CD3XCD20 bispecific antibodies.

P1/2, N=107, Completed, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2

Our results also revealed that the badgers with natural CDV encephalitis presented lesions mostly located in the white matter of the thalamus and cerebellum, suggesting a CDV-specific tropism for the white matter of badger brains in those locations. The knowledge gained in the field of the immunopathogenesis of distemper disease affecting the CNSs of badgers could help to clarify CDV disease patterns in this species.

Conversely, Ph-positive (Ph+) B-ALL patients have been excluded from these trials and are typically managed with tyrosine-kinase inhibitors (TKI) in combination with chemotherapy, steroids, or novel agents such as blinatumomab...A total of 111 patients (93.2%) received TKI treatment, with imatinib being the most common (79%), followed by dasatinib (13.4%) and ponatinib (0.8%)... In real-world practice, rituximab is added to the chemotherapy regimen and TKI in 53.3% of CD20+ Ph+ B-ALL cases. Rituximab is not associated with a higher incidence of infections, ICU admission, early mortality, or deaths in remission. Although there is no significant benefit observed, there is a trend towards better OS with the addition of rituximab to the standard treatment of CD20+ Ph+ ALL.

AZD0486 (formerly TNB-486) is an active treatment in patients with advanced R/R B-NHL and has a predictable safety profile characterized by mainly low-grade AEs and fully transient and reversible CRS/ICANS events. The 2 SUD schedule reduced the overall rate of low grade CRS and ICANS (Grade 1-2) and abrogated Grade 3 events further improving the risk/benefit profile of AZD0486. Dose escalation is ongoing to identify the RP2D.

P2, N=60, Recruiting, Juventas Cell Therapy Ltd. | N=36 --> 60

P1; N=18 --> 36 | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jul 2025 --> Jul 2027

P1/2, N=30, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=18 --> 30

P1/2, N=307, Completed, Kite, A Gilead Company | Active, not recruiting --> Completed

T-cell vitreoretinal lymphoma is rare, and diagnosis can be challenging. Despite inconclusive cytology in this case, interphase fluorescence in situ hybridization detected a JAK2 gene rearrangement, which confirmed the involvement by indolent T-cell lymphoproliferative disorder of the gastrointestinal tract and prompted appropriate treatment and workup for recurrent systemic or central nervous system lymphoma.

P1, N=18, Not yet recruiting, Chinese PLA General Hospital

As far as the authors know here is presented the largest series which compares the phenotype between CLL and its DLBCL-RS. The markers CD19, CD20, CD5, CD79b, CD38, Ki67, and p53 showed relevant changes at the moment of histological transformation. This research enhances the importance of validating reproducible assays to follow hematological malignancies with potential of transformation to more aggressive diseases.

P1, N=40, Recruiting, University Health Network, Toronto

P1, N=40, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting

P1/2, N=38, Recruiting, Chinese PLA General Hospital | Initiation date: Dec 2022 --> Jun 2023

P1, N=55, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2023

GZL is uncommon, usually affects younger patients, is mediastinal and is diagnosed using path morphology and immunophenotype. Patients with newly diagnosed GZL appear to be more sensitive to DLBCL-like immunochemotherapy regimens; relapsed or refractory patients were tended with non-cross-resistant combination chemotherapy or with new drugs.